Nonoxynol-9 Spermicides May Need Review After Clinical Trial Results
This article was originally published in The Tan Sheet
Executive Summary
Appointment of an outside team of investigators to independently review the nonoxynol-9 data generated by the UNAIDS Phase III efficacy trial in the prevention of male-to-female HIV transmission is being urged by Columbia Laboratories.
You may also be interested in...
N-9 Data Warrants Spermicide Safety Study, WHO Report Recommends
The safety of all spermicides should be evaluated in light of recent research indicating the one-time top microbicide candidate nonoxynol-9 actually causes lesions that may facilitate transmission of HIV and other sexually transmitted infections, according to the final report of a "Technical Consultation on N-9," released June 25
Vaginal Lubricants’ Ability To Kill HIV Merits Human Study – Researchers
Clinical trials testing the protective effect of three FDA-approved vaginal lubricants and preparations against HIV should be conducted in populations at high-risk for contracting the virus, University of Texas Medical Branch at Galveston researchers state
Columbia Labs
Class action suit filed in summer 2000 alleging company made "materially misleading statements and omissions" about its nonoxynol-9 spermicide-containing Advantage-S and Rx progesterone gel fertility treatment Crinone dismissed May 9. Class action pertained to stockholders purchasing Columbia shares between Nov. 8, 1999 and June 9, 2000. Advantage-S was found to be ineffective at protecting against HIV in a UNAIDS Phase III trial conducted last year (1"The Tan Sheet" July 17, 2000, p. 8)